4//SEC Filing
Coe Brian 4
Accession 0001209191-21-012510
CIK 0001584751other
Filed
Feb 18, 7:00 PM ET
Accepted
Feb 19, 5:53 PM ET
Size
19.4 KB
Accession
0001209191-21-012510
Insider Transaction Report
Form 4
Coe Brian
DirectorChief Executive Officer
Transactions
- Conversion
Common Stock
2021-02-17+15,082→ 17,637 total(indirect: By LLC) - Conversion
Common Stock
2021-02-17+8,416→ 26,053 total(indirect: By LLC) - Conversion
Series C-1 Preferred Stock
2021-02-17−21,568→ 0 total(indirect: By LLC)→ Common Stock (15,082 underlying) - Conversion
Series F-1 Preferred Stock
2021-02-17−10,630→ 0 total(indirect: By LLC)→ Common Stock (7,433 underlying) - Conversion
Common Stock
2021-02-17+7,433→ 33,486 total(indirect: By LLC) - Conversion
Series E-1 Preferred Stock
2021-02-17−12,035→ 0 total(indirect: By LLC)→ Common Stock (8,416 underlying)
Holdings
- 58,881
Common Stock
- 3,916(indirect: By Trust)
Common Stock
- 3,916(indirect: By Trust)
Common Stock
Footnotes (6)
- [F1]Each share of Series C-1 Preferred Stock automatically converts on a 1-for-1.43 basis into Common Stock at any time at the holder's election and has no expiration date. At the closing of the Issuer's initial public offering, each share of Series C-1 Preferred stock converted into shares of Common Stock, for no additional consideration, at a rate of one share of Common Stock for each 1.43 shares of Series C-1 Preferred Stock.
- [F2]The shares are held by a trust in which Mr. Coe's spouse and children are beneficiaries. Mr. Coe disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
- [F3]Each share of Series E-1 Preferred Stock automatically converts on a 1-for-1.43 basis into Common Stock at any time at the holder's election and has no expiration date. At the closing of the Issuer's initial public offering, each share of Series E-1 Preferred stock converted into shares of Common Stock, for no additional consideration, at a rate of one share of Common Stock for each 1.43 shares of Series E-1 Preferred Stock.
- [F4]Each share of Series F-1 Preferred Stock automatically converts on a 1-for-1.43 basis into Common Stock at any time at the holder's election and has no expiration date. At the closing of the Issuer's initial public offering, each share of Series F-1 Preferred stock converted into shares of Common Stock, for no additional consideration, at a rate of one share of Common Stock for each 1.43 shares of Series F-1 Preferred Stock.
- [F5]The shares are held by Jason Coe Irrevocable Gift Trust, for which Mr. Coe is a trustee. Mr. Coe disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
- [F6]The shares are held by Lillian Coe Irrevocable Gift Trust, for which Mr. Coe is a trustee. Mr. Coe disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
Documents
Issuer
Talis Biomedical Corp
CIK 0001584751
Entity typeother
Related Parties
1- filerCIK 0001845260
Filing Metadata
- Form type
- 4
- Filed
- Feb 18, 7:00 PM ET
- Accepted
- Feb 19, 5:53 PM ET
- Size
- 19.4 KB